CN117356707A - Functional food composition for preventing and treating three-high symptoms and preparation method thereof - Google Patents
Functional food composition for preventing and treating three-high symptoms and preparation method thereof Download PDFInfo
- Publication number
- CN117356707A CN117356707A CN202311413503.7A CN202311413503A CN117356707A CN 117356707 A CN117356707 A CN 117356707A CN 202311413503 A CN202311413503 A CN 202311413503A CN 117356707 A CN117356707 A CN 117356707A
- Authority
- CN
- China
- Prior art keywords
- parts
- treating
- functional food
- preventing
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 235000013376 functional food Nutrition 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 208000024891 symptom Diseases 0.000 title abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 30
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 28
- 235000004347 Perilla Nutrition 0.000 claims abstract description 27
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 24
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 23
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 23
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 23
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 18
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 16
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 16
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 16
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 16
- 235000008397 ginger Nutrition 0.000 claims abstract description 16
- 241000756042 Polygonatum Species 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims abstract description 12
- 239000008187 granular material Substances 0.000 claims abstract description 11
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 7
- 244000088415 Raphanus sativus Species 0.000 claims abstract description 5
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 4
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 241000245665 Taraxacum Species 0.000 claims description 19
- 238000004140 cleaning Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 6
- 239000000845 maltitol Substances 0.000 claims description 6
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 6
- 229940035436 maltitol Drugs 0.000 claims description 6
- 235000010449 maltitol Nutrition 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000007493 shaping process Methods 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000723353 Chrysanthemum Species 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000036541 health Effects 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 8
- 235000018927 edible plant Nutrition 0.000 abstract description 2
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 35
- 230000000694 effects Effects 0.000 description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 241000220259 Raphanus Species 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 14
- 230000000144 pharmacologic effect Effects 0.000 description 14
- 241001570521 Lonicera periclymenum Species 0.000 description 13
- 230000009471 action Effects 0.000 description 13
- 230000001603 reducing effect Effects 0.000 description 13
- 241001092040 Crataegus Species 0.000 description 12
- 239000000284 extract Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 241000234314 Zingiber Species 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 201000001421 hyperglycemia Diseases 0.000 description 9
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000628997 Flos Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010040925 Skin striae Diseases 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 5
- 235000002780 gingerol Nutrition 0.000 description 5
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- -1 Convallaria majalis Chemical class 0.000 description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001633680 Polygonatum odoratum Species 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000657480 Crataegus pinnatifida Species 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 241000589902 Leptospira Species 0.000 description 3
- 244000167230 Lonicera japonica Species 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-SNVBAGLBSA-N (-)-α-limonene Chemical compound CC(=C)[C@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-SNVBAGLBSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N Chelidonic acid Chemical compound OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 244000068485 Convallaria majalis Species 0.000 description 2
- 235000009046 Convallaria majalis Nutrition 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- 241000229143 Hippophae Species 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000017617 Lonicera japonica Nutrition 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- RUMOYJJNUMEFDD-UHFFFAOYSA-N perillyl aldehyde Chemical compound CC(=C)C1CCC(C=O)=CC1 RUMOYJJNUMEFDD-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- HUJXHFRXWWGYQH-UHFFFAOYSA-O sinapine Chemical compound COC1=CC(\C=C\C(=O)OCC[N+](C)(C)C)=CC(OC)=C1O HUJXHFRXWWGYQH-UHFFFAOYSA-O 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 235000015487 sulforaphane Nutrition 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000001841 zingiber officinale Substances 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- IECBDTGWSQNQID-JGVFFNPUSA-N (1r,5s)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-7-one Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2=O IECBDTGWSQNQID-JGVFFNPUSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- ZWSNUPOSLDAWJS-QNDFHXLGSA-N 6,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound OC[C@H]1O[C@@H](Oc2ccc(cc2)-c2coc3cc(O)c(O)cc3c2=O)[C@H](O)[C@@H](O)[C@@H]1O ZWSNUPOSLDAWJS-QNDFHXLGSA-N 0.000 description 1
- 210000002925 A-like Anatomy 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010002515 Animal bite Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- IECBDTGWSQNQID-UHFFFAOYSA-N Chrysanthenon Natural products CC1=CCC2C(C)(C)C1C2=O IECBDTGWSQNQID-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-SFYZADRCSA-N Chrysanthenone Natural products CC1=CC[C@H]2C(C)(C)[C@@H]1C2=O IECBDTGWSQNQID-SFYZADRCSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000755716 Convallaria Species 0.000 description 1
- 241000207894 Convolvulus arvensis Species 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- 241000100289 Lonicera confusa Species 0.000 description 1
- 241000173699 Lonicera dasystyla Species 0.000 description 1
- 241001170080 Lonicera hypoglauca Species 0.000 description 1
- 241001170076 Lonicera macranthoides Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 241001092489 Potentilla Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000019057 Raphanus caudatus Nutrition 0.000 description 1
- 235000011380 Raphanus sativus Nutrition 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 241001058321 Taraxacum sinicum Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001309 inhibitory effect on influenza Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002013 molluscicidal effect Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000010383 shanzha Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a functional food composition for preventing and treating three-high symptoms, which is prepared from the following medicinal materials in parts by weight: 3 to 750 parts of hawthorn, 3 to 600 parts of sea buckthorn, 6 to 450 parts of fragrant solomonseal rhizome, 4 to 450 parts of kudzuvine root, 8 to 525 parts of honeysuckle, 2 to 600 parts of dandelion, 3 to 450 parts of perilla, 5 to 750 parts of radish seed, 3 to 600 parts of dried ginger and 6 to 450 parts of chrysanthemum. The raw materials in the formula of the invention adopt medicinal and edible plant medicines, so that not only can the three-high symptoms be prevented and treated, but also the intravascular garbage can be removed, the cell vitality can be enhanced, the purpose of health care can be achieved, and the health care concept of 'green health' can be met. The invention also discloses a preparation method of the functional food granule and the ointment for preventing and treating the three-high disease.
Description
Technical Field
The invention relates to a functional food composition for preventing and treating three-high symptoms. The invention also relates to a preparation method of the functional food composition for preventing and treating the three-high symptoms.
Background
The concept of "three highs" is now known by more people, and generally refers to three conditions closely related to sub-health, namely hyperlipidemia, hyperglycemia and hypertension, and the health problems caused by the changes of life type and eating habits are not only faced by the elderly, but also the problems of hypertension, diabetes, stroke and the like of more and more twenty to fifty-year old people in advance due to higher blood pressure, higher blood sugar and higher cholesterol. Hyperlipidemia can cause atherosclerosis thrombosis, and further develop into cerebral infarction; hypertension can cause cerebral hemorrhage and cerebral vascular rupture; hyperglycemia can cause renal failure and retinopathy.
The three highs are not independent, but closely related and mutually influenced, so that as long as one disease is suffered, the other two diseases are quickly brought up: patients with diabetes are prone to hypertension or hyperlipidemia; hyperlipidemia is the "root" and "accelerator" of atherosclerosis; the atherosclerosis aggravates the rise of blood pressure due to poor vascular elasticity, causing hypertension.
The three-high disease is associated with hands, so that organs such as heart, liver, brain, kidney and the like are damaged together, various complications are induced, cardiovascular and cerebrovascular diseases and renal failure can be seriously caused, even death is caused, and a plurality of people smell the three-high disease color change.
In clinic, western medicines are generally used for reducing blood pressure, blood sugar and blood lipid at present, and the medicines have large side effects, so that the aim of treating both principal and secondary aspect of disease can not be achieved, and some medicines also have drug withdrawal reaction, so that pain is increased for people.
Disclosure of Invention
The invention aims to solve the technical problem of providing a functional food composition for preventing and treating three-high symptoms, which uses Chinese herbal medicines with homology of medicine and food and can prevent and treat the three-high symptoms by regulating the function balance of a human body.
In order to solve the technical problems, the technical solution of the functional food composition for preventing and treating the three-high disease is that the functional food composition is prepared from the following medicinal materials in parts by weight:
3 to 750 parts of hawthorn, 3 to 600 parts of sea buckthorn, 6 to 450 parts of fragrant solomonseal rhizome, 4 to 450 parts of kudzuvine root, 8 to 525 parts of honeysuckle, 2 to 600 parts of dandelion, 3 to 450 parts of perilla, 5 to 750 parts of radish seed, 3 to 600 parts of dried ginger and 6 to 450 parts of chrysanthemum.
In another embodiment, the composition further comprises a pharmaceutically acceptable carrier.
The invention also provides a preparation method of the functional food granule for preventing and treating the three highs, which adopts the technical proposal that the preparation method comprises the following steps:
(1) weighing the medicinal materials according to the following weight ratio, and cleaning;
3 to 50 parts of hawthorn, 3 to 40 parts of sea buckthorn, 6 to 30 parts of fragrant solomonseal rhizome, 4 to 30 parts of kudzuvine root, 8 to 35 parts of honeysuckle, 2 to 40 parts of dandelion, 3 to 30 parts of perilla, 5 to 50 parts of radish seed, 3 to 40 parts of dried ginger and 6 to 30 parts of chrysanthemum;
(2) drying the medicinal materials, and grinding into powder;
(3) the medicinal material powder is fully mixed and then sterilized at high temperature;
(4) adding excipient, shaping and granulating to form granules;
(5) sterilizing at high temperature again.
The invention also provides a preparation method of the functional food paste for preventing and treating the three highs, which adopts the technical proposal that the preparation method comprises the following steps:
(1) weighing the medicinal materials according to the following weight ratio, cleaning, and concentrating, decocting, removing residues, and collecting concentrated juice;
45-750 parts of hawthorn, 45-600 parts of sea buckthorn, 30-450 parts of polygonatum, 50-450 parts of kudzuvine root, 20-525 parts of honeysuckle, 50-600 parts of dandelion, 30-450 parts of perilla, 20-750 parts of radish seed, 10-600 parts of dried ginger and 20-450 parts of chrysanthemum;
(2) adding 200-500 parts of isomaltooligosaccharide and 200-500 parts of maltitol, and melting to obtain the cream.
The invention also provides application of the food composition in preparing functional food for preventing and treating three-high symptoms.
The invention has the following technical effects:
the components of the invention are mutually carried, the bioavailability is high, and the invention can clear internal stagnation, such as phlegm, turbid urine, blood stasis, excessive heat and the like, open the running channel of the ventilator, increase the driving force and adjust the whole state of qi and blood running, thereby improving viscera functions.
The invention starts from two aspects of symptoms and root causes of the three-high symptoms, aims at the clinical indexes of the three-high symptoms to treat the symptoms on one hand, and comprehensively adjusts the human body by combining the forces of the medicines to achieve the aim of treating the root cause on the other hand. The raw materials in the formula adopt medicinal and edible plant medicines, so that not only can the three-high symptoms be prevented and treated, but also the intravascular garbage can be removed, the cell vitality can be enhanced, the purpose of health care can be achieved, and the health care concept of 'green health' is met.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention are clearly and completely described below. It will be apparent that the described embodiments are some, but not all, embodiments of the invention. All other embodiments, which can be made by a person skilled in the art without creative efforts, based on the described embodiments of the present invention fall within the protection scope of the present invention. Unless otherwise defined, technical or scientific terms used herein should be given the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs.
The invention relates to a functional food composition for preventing and treating three-high symptoms, which is prepared from the following medicinal materials in parts by weight:
3 to 750 parts of hawthorn, 3 to 600 parts of sea buckthorn, 6 to 450 parts of fragrant solomonseal rhizome, 4 to 450 parts of kudzuvine root, 8 to 525 parts of honeysuckle, 2 to 600 parts of dandelion, 3 to 450 parts of perilla, 5 to 750 parts of radish seed, 3 to 600 parts of dried ginger and 6 to 450 parts of chrysanthemum.
Preferably, it further comprises a pharmaceutically acceptable carrier.
The efficacy of each component of the invention is as follows:
(1) Hawthorn (shanzha) Crataegi frames:
mature fruit of the rose family plant, mountain red Crataegus pinnatifida bge.var.major N.E.Br. or Crataegus pinnatifida bge.
The chemical components are as follows: fructus crataegi contains flavonoids, triterpene saponins (ursolic acid, oleanolic acid, crataegolic acid, etc.), saponin tannins, free acids, fatty acids, vitamin C, inorganic salts, and red pigment.
Pharmacological action: the fatty acid can promote fat digestion, increase secretion of gastric digestive enzyme to promote digestion, and has certain regulating effect on gastrointestinal function. The extract can dilate coronary artery, increase coronary flow, and protect myocardial ischemia and anoxia; and has effects in tonifying heart, lowering blood pressure, and relieving arrhythmia; also reducing blood lipid, anti-atherosclerosis, which lowers serum cholesterol and triglycerides, may be achieved by increasing the concentration of high density cholesterol and its subfractions in the serum, increasing cholesterol excretion. In addition, haw can resist platelet aggregation, resist oxidation, strengthen immunity, induce diuresis, calm, shrink uterus, inhibit bacteria, etc.
(2) Sea buckthorn (shaj i) Hippophae Fructus:
mature fruit of Hippophae rhamnoides L.
The chemical components are as follows: contains multiple physiologically active substances. Mainly comprises vitamins, isorhamnetin, proteins, carotene, amino acids, amides, flavonoids, apigenin, quercetin, kaempferol, beta-sitosterol, cryptoxanthin, saccharides, organic acids, steroic acids, fatty acids, lipids and microelements.
Pharmacological action: has effects in reducing blood lipid, relieving cough, and eliminating phlegm; can regulate digestion function and promote ulcer healing; can enhance immunity; an anti-tumor; improving cardiovascular system function; promoting hematopoiesis; reducing the viscosity of whole blood; inhibiting platelet aggregation; lowering serum total cholesterol, and increasing serum high density lipoprotein cholesterol and liver total cholesterol; inhibiting formation of experimental thrombus; protecting liver; anti-gastric ulcer; oxidation resistance; anti-inflammatory; increasing phagocytic function of reticuloendothelial system; antiallergic agent. The oleum Hippophae has certain effects of resisting tumor, depression and radiation. (Hua Xiyao journal 2020,35 (02): 211-217)
(3) Polygonatum odoratum (yuzhu) polygonatum odoratum (Polygonatum odoratum):
is rhizome of Druce. Of Polygonatum odoratum Polygonatum odoratum (Mill.) of Liliaceae.
The chemical components are as follows: the product contains steroid saponin (such as Convallaria majalis, and Convallaria majalis), flavone and its glycoside (such as elyseginoside), microelements, amino acid and other nitrogen-containing compounds, and also contains mucin, chelidonic acid, and vitamin A-like substance.
Pharmacological action: the product has effects of promoting antibody production of experimental animal, increasing phagocytic percentage and phagocytic index of macrophage, promoting interferon synthesis, inhibiting tubercle bacillus growth, reducing blood sugar, reducing blood lipid, relieving atherosclerosis plaque formation, dilating peripheral blood vessel and coronary artery, prolonging anoxia resisting time, strengthening heart, resisting oxidation, and resisting aging. Also has corticoid-like effects. The pharmacological action of Convallaria majaside in rhizome is the same as that of Convolvulus arvensis glycoside K, and has effects of tonifying heart, promoting urination, and tranquilizing.
(4) Radix Puerariae (gegen) Radix Puerariae (Radix Puerariae) ray Puerariae:
is the root of Pueraria lobata (Willd.) Ohwi of Leguminosae.
The chemical components are as follows: the product mainly contains flavonoid such as daidzin, daidzein, puerarin, etc., and also contains daidzein-4, 7-glucoside, puerarin-7-xyloside, puerarin, and isoflavone glycoside and starch.
Pharmacological action: pueraria decoction, alcoholic infusion, total flavonoids, daidzin and puerarin can be used for treating acute myocardial ischemia caused by posterior pituitrin. The radix Puerariae total flavone can dilate coronary blood vessel and cerebral blood vessel, increase coronary blood flow and cerebral blood flow, reduce myocardial oxygen consumption, and increase oxygen supply. The radix puerariae can directly dilate blood vessels, so that peripheral resistance is reduced, the blood pressure is obviously reduced, and the 'tightening' symptoms of patients with hypertension can be well relieved. Puerarin can improve microcirculation, increase local micro blood flow, and inhibit blood platelet aggregation. Pueraria has wide beta-receptor blocking effect. Has obvious spasmolytic effect on isolated intestinal canal of mice, and can resist intestinal canal spasm caused by acetylcholine. Pueraria lobata has also an obvious antipyretic effect. The oral puerarin can obviously reduce the blood sugar of the mice with the tetraoxypyrimidine hyperglycemia, reduce the content of serum cholesterol, strengthen the blood sugar reducing effect after selecting the compound formed by the puerarin with the lowest effective dose and the small (invalid) aspirin, can maintain for more than 24 hours, can obviously improve the sugar tolerance of the mice with the tetraoxypyrimidine hyperglycemia, obviously resist the blood sugar increasing effect of epinephrine, and is considered that the puerarin can be the main component of the puerarin for treating diabetes. The oral radix Puerariae decoction can be used for preventing the phenomenon of lowering of apoA-I in blood and increasing of cholesterol and triglyceride of drinking rats due to ethanol.
(5) Dandelion (pugongying) TaraxaciHerba:
the Asteraceae plant dandelion Taraxacum mongolicum hand-Mazz, taraxacum alkali T.sinicum Kitag, or dried whole herb of several plants of the same genus.
The chemical components are as follows: the product contains taraxasterol, taraxacin, inositol, lettuce alcohol, and taraxacum. Caffeic acid, resin, etc.
Pharmacological action: the decoction or infusion has strong inhibition effect on staphylococcus aureus, hemolytic streptococcus and catarrhal coccus, also has certain inhibition effect on pneumococcus, meningococcus, diphtheria bacillus, shigella flexneri, pseudomonas aeruginosa, leptospira and the like, and has synergism between TMP (sulfanilamide synergist). Has the functions of promoting the function of gallbladder, protecting liver, resisting endotoxin and promoting urination, and has more remarkable effect than the herba artemisiae capillaries decoction. The herba Taraxaci aerial part water extract can activate macrophage and has anti-tumor effect. In vitro experiments indicate that the product can excite the immune function of organisms. Clinical studies have reported that dandelions can be used for other diseases, such as: the dandelion decoction is used together with hawthorn, mistletoe, astragalus and shizandra berry for treating 37 cases of hyperlipidemia, 35 cases of which have good effects (new traditional Chinese medicine, 1988, 2:28) Zhao Xiu and the like, and the research proves that the dandelion decoction can reduce the blood sugar and blood fat level of diabetic mice, and is used together with potentilla flavone, so that the effects of reducing blood sugar and blood fat are better. (modern journal of Chinese and Western medicine combination 2021,30 (05): 563-567.)
(6) Honeysuckle (jinyinhua) LoniceraeJaponicae Flos:
is dried flower bud or flower with primary opening of lonicera japonica of Caprifoliaceae Lonicera japonica thunder, lonicera rubra L.hypoglauca Miq, lonicera japonica L.confusa DC, or lonicera macranthoides L.dasystyla red.
The chemical components are as follows: the product contains volatile oil, luteolin, inositol, flavonoids, inositol, saponin, tannin, etc. The separated chlorogenic acid and isochlorogenic acid are main components of the product for resisting bacteria.
Pharmacological action: the product has broad-spectrum antibacterial effect, and can inhibit pathogenic bacteria such as Staphylococcus aureus, bacillus dysenteriae, etc., and pathogenic microorganisms such as Leptospira, influenza virus, pathogenic mold, etc.; the flos Lonicerae decoction can promote phagocytosis of leukocyte: has obvious anti-inflammatory and antipyretic effects. The product has cholesterol reducing effect. The water and alcohol infusion has obvious cytotoxicity on sarcoma 180 and Ehrlich ascites tumor. In addition, a large amount of oral administration has a preventive effect on experimental gastric ulcer. Has certain excitation effect on central nerve. In experiments for researching the influence of honeysuckle on hyperglycemia mice, the honeysuckle extract has good effect of reducing the blood sugar of model mice with tetraoxypyrimidine and sucrose hyperglycemia. (journal of Chinese laboratory prescriptions, 2019,25 (04): 225-234)
(7) Perilla leaf (zisuye) Perillae Folium:
is leaf of Perilla Perilla frutescens (L.) Britt.
The chemical components are as follows: the product contains volatile oil, mainly perillaldehyde, L-limonene, and small amount of a-pinene.
Pharmacological action: the Perilla leaf decoction has mild antipyretic effect; has effects in promoting secretion of digestive juice and promoting gastrointestinal motility; can reduce bronchosecretion and relieve bronchospasm; the water decoction has inhibiting effect on colibacillus, dysentery bacillus and staphylococci. Perilla oil can shorten blood coagulation time, blood plasma calcium recovery time and thromboplastin time, and Perilla oil can raise blood sugar. Sun Anping the experiment proves that the perilla leaf polysaccharide can improve liver injury of rats with type II diabetes, can obviously reduce Fasting Blood Glucose (FBG), triglyceride (TG) and Total Cholesterol (TC) levels in the rats with type II diabetes, and has the effects of reducing blood glucose and blood lipid. (Chinese journal of Chinese medicine: 1-10[2023-01-12 ]) Perillae herba and its volatile oil have remarkable therapeutic effect in treating cardiovascular and cerebrovascular diseases, and high safety. Zhou Qinmei and the like systematically explore the vasodilation effect of the perilla leaf volatile oil and the active substances thereof, prove that the perilla leaf volatile oil has remarkable vasodilation effect on KCI pre-contracted isolated rat thoracic aortic annulus, and presumably the action mechanism is that the inflow of extracellular Ca2+ is reduced by influencing the opening of KCI-induced voltage-dependent calcium channels (VDCCs). The research shows that PAE has certain vasodilation effect. (journal of Chinese laboratory prescriptions, 2021,27 (13): 215-225.)
(8) Radish seed (laifuzi) Raphani segment:
is mature seed of Raphanus sativus L.
The chemical components are as follows: radish seed contains sulforaphane, sinapine, fatty oil (oil contains a large amount of erucic acid, linoleic acid and linolenic acid), beta-sitosterol, saccharides, various amino acids, vitamins and the like.
Pharmacological action: the radish seed extract has the advantages of mild and continuous antihypertensive effect, stable effect, strong repeatability and no obvious toxic or side effect; the blood pressure lowering effect of the injection is related to the drug concentration. Radish seed can enhance the rhythmic contraction of the ileum of an isolated rabbit and inhibit gastric emptying of a mouse. Has stronger antibacterial activity to various gram-positive bacteria and negative bacteria in vitro; the concentration of 1mg/ml of the sulforaphane can obviously inhibit staphylococcus and escherichia coli; the water extract (1:3) has various degrees of inhibition on 6 dermatophytes such as trichophyton concentricus in a test tube. Radish seed also has the functions of resisting bacteria, eliminating phlegm, relieving cough, relieving asthma, improving urination, reducing cholesterol, preventing arteriosclerosis, etc. Radish seeds can neutralize tetanus toxin and diphtheria toxin in vitro.
(9) Zingiber officinale (ganj iang) zingiberis rhizoma:
is dried rhizome of ginger Zingiber officinale Rosc.
The chemical components are as follows: the rhizoma Zingiberis contains about 2% of volatile oil, and contains zingiberene, phellandrene, embedded ethylene, jiang Xitong, gingerol, borneol, gingerol, citral, etc. Further comprises resin, starch, and multiple amino acids.
Pharmacological action: the stem Jiang Jinji can enhance the autonomous movement of the isolated heart. The rats were given an intravenous injection of dry Jiang Jinji 0.25.25 g/kg, which showed a transient pressure increasing and subsequent pressure decreasing effect and enhanced atrial autonomic activity. The zingiber officinale ether extract is 1.5ml/kg and 3.0ml/kg for gastric lavage, so that the oxygen consumption rate of the whole mice can be reduced, and the survival time of mice with normal-pressure closed hypoxia and KCN poisoning hypoxia models can be prolonged. The methanol extract of rhizoma Zingiberis recens has effects in reducing serum cholesterol, inhibiting increase of total cholesterol/phospholipid ratio in blood, and relieving atherosclerosis. The methanol or ether extract of rhizoma Zingiberis has tranquilizing, analgesic, antiinflammatory, and antiemetic effects; the water extract or the volatile oil can obviously prolong the experimental thrombosis time of the rats; the gingerol extract and gingerol and Jiang Laxi ketone contained therein have remarkable molluscicidal and anti-schistosome effects. The gingerol extract can obviously increase the bile secretion of rat liver and can be maintained for 3-4 hours.
(10) Chrysanthemum (juhua) Chrysanthemi Flos:
is a dry head flower of chrysanthemum Chrysanthemum morifolium Ramat.
The chemical components are as follows: the product contains volatile oil, which is borneol, camphor, chrysanthenone, etc., and also contains chrysantheside, adenine, choline, flavone, stachydrine, vitamin A, vitamin B1, vitamin E, amino acid, locust element, etc.
Pharmacological action: the chrysanthemum water soaking agent or decoction has certain antibacterial effect on staphylococcus aureus, various pathogenic bacilli and dermatophytes. The product also has inhibitory effect on influenza virus PR3 and leptospira. The flos Chrysanthemi preparation has effects of dilating coronary artery, increasing coronary blood flow, increasing myocardial oxygen consumption, lowering blood pressure, shortening clotting time, relieving fever, relieving inflammation, and tranquilizing. Experiments of chrysanthemum extract on the influence of blood fat of rats fed with high-fat feed show that the extract has obvious improvement effect on the rise of serum cholesterol of rats. The flos Chrysanthemi extract can reduce blood sugar of diabetic mice. The chrysanthemum total flavone can improve the morbidity symptoms of diabetic mice, promote the growth of the quality of the mice, and obviously reduce the blood glucose level and the glucose tolerance level. (Chinese herbal medicine, 2019,50 (19): 4785-4795.)
From a pharmacological point of view: (1) the pharmacological actions of the medicines on three highs mainly reduce and take account of bidirectional regulation. (2) All the medicines have pharmacological support for improving the functions of the cardiovascular system. (3) Some herbs in the recipe can enhance the immune system. (4) The several Chinese medicinal materials in the recipe have the functions of resisting bacteria and diminishing inflammation. (5) The whole prescription has better conditioning effect on people with easy irritability or unstable emotion.
From a traditional medical point of view: the medicine disclosed by the invention fully covers pathological factors such as blood stasis, turbid phlegm, food stagnation, accumulated heat and the like which are generated in a human body, has the effects of resolving stagnation, removing stagnation, resolving carbuncles, detoxifying, regulating urination and defecation, calming intestines and stomach, promoting blood circulation and the like, ensures that pathogenic factors have a way and five viscera are safe, can treat the existing uncomfortable symptoms, and can also play a role in treating the disease. It is particularly worth pointing out that the purple perilla and the kudzuvine root in the recipe both have the efficacy of detoxification, especially detoxification caused by food. Pueraria root can dispel various toxins, especially alcohol toxicity, and Perillae herba can dispel fish and crab toxicity and treat dog and snake bite. To cope with the dietary safety problem of the society today, it is necessary to add these two drugs. To date, perilla leaves are consumed in large quantities in northeast and japan to cover foods, especially raw foods.
The qi and blood flow of the human body is circulation, and the qi and blood flow is ascending and descending. Through lifting, the important nodes in the lifting device are communicated. The qi and blood circulation is blocked, and the circulation of qi and blood is stabilized by the promotion and actuation of the drug efficacy. The four herbs of Pueraria lobata, radish seed, perillae herba and Chrysanthemum in the present invention are all used when they act on qi and blood. The qi movement of the middle warmer is to promote the movement of the Chinese medicinal materials (radix Puerariae, perillae herba, and Raphani semen); the blood circulation promoting (chrysanthemum) and the wind removing (chrysanthemum) are open roads; the heart meridian (Perilla herb) and the striae and sweat pores (Pueraria lobata) are the passages for opening the upper energizer and guiding upward. The function of the kudzuvine root of opening striae is not negligible, and the formula of the auxiliary row is cloud: the lung bitter qi flowing upwards and being pungent and easy to eat and dissipate, the striae and sweat pores being opened to ventilate are said to come from the decoction menstruation method. "jin Kui Yao Chart: the striae and striae are the true points of the three-jiao, the points of qi and blood, and the texture of the viscera. "
The invention relates to a preparation method of functional food granules for preventing and treating three highs, which comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, and cleaning;
2. drying the medicinal materials, and grinding into powder;
3. the medicinal material powder is fully mixed and then sterilized at high temperature;
4. adding excipient, shaping and granulating to form fine particles;
5. sterilizing at high temperature again.
The invention relates to a preparation method of a functional food paste for preventing and treating three highs, which comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, cleaning, and concentrating, decocting, removing residues, and collecting concentrated juice;
2. adding 13-500 parts of isomaltooligosaccharide and 13-500 parts of maltitol, and melting to obtain the cream.
Example 1
A functional food granule for preventing and treating three highs is prepared from the following raw materials:
3 parts of hawthorn, 3 parts of sea buckthorn, 6 parts of fragrant solomonseal rhizome, 4 parts of kudzuvine root, 8 parts of honeysuckle, 2 parts of dandelion, 3 parts of perilla, 5 parts of radish seed, 3 parts of dried ginger and 6 parts of chrysanthemum.
The preparation method comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, and cleaning;
2. drying the medicinal materials, and grinding into powder;
3. fully mixing the medicinal material powder, and sterilizing at a high temperature of above 100deg.C;
4. adding excipient, shaping and granulating to form fine particles;
5. and sterilizing at high temperature above 100deg.C.
Example 2
A functional food granule for preventing and treating three highs is prepared from the following raw materials:
5 parts of hawthorn, 5 parts of sea buckthorn, 10 parts of fragrant solomonseal rhizome, 6 parts of kudzuvine root, 13 parts of honeysuckle, 3 parts of dandelion, 5 parts of perilla, 8 parts of radish seed, 5 parts of dried ginger and 10 parts of chrysanthemum.
The preparation method comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, and cleaning;
2. drying the medicinal materials, and grinding into powder;
3. fully mixing the medicinal material powder, and sterilizing at a high temperature of above 100deg.C;
4. adding excipient, shaping and granulating to form fine particles;
5. and sterilizing at high temperature above 100deg.C.
Example 3
A functional food granule for preventing and treating three highs is prepared from the following raw materials:
50 parts of hawthorn, 50 parts of sea buckthorn, 100 parts of fragrant solomonseal rhizome, 66 parts of kudzuvine root, 133 parts of honeysuckle, 33 parts of dandelion, 50 parts of perilla, 83 parts of radish seed, 50 parts of dried ginger and 100 parts of chrysanthemum.
The preparation method comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, and cleaning;
2. drying the medicinal materials, and grinding into powder;
3. fully mixing the medicinal material powder, and sterilizing at a high temperature of above 100deg.C;
4. adding excipient, shaping and granulating to form fine particles;
5. and sterilizing at high temperature above 100deg.C.
Example 4
A functional food paste for preventing and treating three highs is prepared from the following raw materials:
45 parts of hawthorn, 45 parts of sea buckthorn, 30 parts of fragrant solomonseal rhizome, 50 parts of kudzuvine root, 20 parts of honeysuckle, 50 parts of dandelion, 30 parts of perilla, 20 parts of radish seed, 10 parts of dried ginger and 20 parts of chrysanthemum.
The preparation method comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, cleaning, and concentrating, decocting, removing residues, and collecting concentrated juice;
2. adding 200 parts of isomaltooligosaccharide and 200 parts of maltitol, and melting and collecting paste.
Example 5
A functional food paste for preventing and treating three highs is prepared from the following raw materials:
50 parts of hawthorn, 20 parts of sea buckthorn, 30 parts of fragrant solomonseal rhizome, 50 parts of kudzuvine root, 20 parts of honeysuckle, 50 parts of dandelion, 30 parts of perilla, 20 parts of radish seed, 10 parts of dried ginger and 20 parts of chrysanthemum.
The preparation method comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, adding 8 times of water after cleaning, decocting for 1 hour, removing residues, and taking thick juice;
2. adding 200 parts of isomaltooligosaccharide and 200 parts of maltitol, and melting and collecting paste.
Example 6
A functional food paste for preventing and treating three highs is prepared from the following raw materials:
750 parts of hawthorn, 600 parts of sea buckthorn, 450 parts of fragrant solomonseal rhizome, 450 parts of kudzuvine root, 525 parts of honeysuckle, 600 parts of dandelion, 450 parts of perilla, 750 parts of radish seed, 600 parts of dried ginger and 450 parts of chrysanthemum.
The preparation method comprises the following steps:
1. weighing the medicinal materials according to the weight ratio, adding 6 times of water after cleaning, decocting for 1 hour, removing residues, and taking thick juice;
2. adding 500 parts of isomaltooligosaccharide and 500 parts of maltitol, and melting to obtain the cream.
Comparative example 1
In the comparative example, on the basis of the example 1, the medicine of kudzuvine root is not used, and the preparation method is the same as that of the example 1.
Comparative example 2
In this comparative example, on the basis of example 1, the preparation method of the same as that of example 1 was carried out by using less perilla herb.
Comparative example 3
The comparative example is based on the example 1, the radish seed is used less as a medicament, and the preparation method is the same as that of the example 1.
Comparative example 4
The comparative example is based on example 4, and the preparation method of the comparative example is the same as that of example 4, except that the chrysanthemum is used as the drug.
Comparative example 5
The comparative example is based on the example 4, three medicines of kudzuvine root, purple perilla and radish seed are used less, and the preparation method is the same as that of the example 4.
Comparative example 6
The comparative example is based on the example 4, and four medicines of kudzuvine root, radish seed, purple perilla and chrysanthemum are used less, and the preparation method is the same as that of the example 4.
The effect test of the invention is as follows:
6 patients with hyperlipidemia, 6 patients with hypertension and 12 patients with hyperglycemia are divided into 12 observation groups and 12 control groups (3 patients with hyperlipidemia, 3 patients with hypertension and 6 patients with hyperglycemia respectively).
The observation group 12 persons were divided into six groups, and the granule preparation or the paste preparation of examples 1 to 6 was taken for 21 days, and the health condition of the 12 persons was examined, and the examination results are shown in table 1.
TABLE 1
Detection result: the blood lipid index, blood pressure index and blood glucose index corresponding to each disease patient are obviously reduced, wherein the average reduction rate of the patients with hyperlipidemia is 18.8%, the average reduction rate of the patients with hypertension is 6.3%, and the average reduction rate of the patients with hyperglycemia is 9.6%. During the administration period, some patients have symptoms such as tinnitus, dizziness and the like, obviously improve symptoms of gastrointestinal tract, such as constipation, abdominal distension and other uncomfortable symptoms, and have light self-sense body and good spirit after administration, and have no adverse reaction. The invention has obvious curative effect and small side effect on the three-high disease.
The control group of 12 persons was divided into six groups, and the granule preparation or the paste preparation of comparative examples 1 to 6 was taken respectively, and the health condition of the 12 persons was examined after 21 days of taking, and the examination results are shown in Table 2.
TABLE 2
Detection result: the blood pressure index, the blood fat index and the blood sugar index corresponding to patients with various diseases are not obviously reduced.
The foregoing has shown and described the basic principles and main features of the present invention and the advantages of the present invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that the above embodiments and descriptions are merely illustrative of the principles of the present invention, and various changes and modifications may be made without departing from the spirit and scope of the invention, which is defined in the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (5)
1. The functional food composition for preventing and treating the three-high disease is characterized by being prepared from the following medicinal materials in parts by weight:
3 to 750 parts of hawthorn, 3 to 600 parts of sea buckthorn, 6 to 450 parts of fragrant solomonseal rhizome, 4 to 450 parts of kudzuvine root, 8 to 525 parts of honeysuckle, 2 to 600 parts of dandelion, 3 to 450 parts of perilla, 5 to 750 parts of radish seed, 3 to 600 parts of dried ginger and 6 to 450 parts of chrysanthemum.
2. The functional food composition for preventing and treating hyperlipidemia according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
3. The preparation method of the functional food granule for preventing and treating the three highs is characterized by comprising the following steps of:
(1) weighing the medicinal materials according to the following weight ratio, and cleaning;
3 to 50 parts of hawthorn, 3 to 40 parts of sea buckthorn, 6 to 30 parts of fragrant solomonseal rhizome, 4 to 30 parts of kudzuvine root, 8 to 35 parts of honeysuckle, 2 to 40 parts of dandelion, 3 to 30 parts of perilla, 5 to 50 parts of radish seed, 3 to 40 parts of dried ginger and 6 to 30 parts of chrysanthemum;
(2) drying the medicinal materials, and grinding into powder;
(3) the medicinal material powder is fully mixed and then sterilized at high temperature;
(4) adding excipient, shaping and granulating to form granules;
(5) sterilizing at high temperature again.
4. The preparation method of the functional food paste for preventing and treating the three highs is characterized by comprising the following steps of:
(1) weighing the medicinal materials according to the following weight ratio, cleaning, and concentrating, decocting, removing residues, and collecting concentrated juice;
45-750 parts of hawthorn, 45-600 parts of sea buckthorn, 30-450 parts of polygonatum, 50-450 parts of kudzuvine root, 20-525 parts of honeysuckle, 50-600 parts of dandelion, 30-450 parts of perilla, 20-750 parts of radish seed, 10-600 parts of dried ginger and 20-450 parts of chrysanthemum;
(2) adding 200-500 parts of isomaltooligosaccharide and 200-500 parts of maltitol, and melting to obtain the cream.
5. Use of a food composition according to any one of claims 1-2 for the preparation of a functional food for the prevention and treatment of hyperlipidemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311413503.7A CN117356707A (en) | 2023-10-30 | 2023-10-30 | Functional food composition for preventing and treating three-high symptoms and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311413503.7A CN117356707A (en) | 2023-10-30 | 2023-10-30 | Functional food composition for preventing and treating three-high symptoms and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117356707A true CN117356707A (en) | 2024-01-09 |
Family
ID=89394439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311413503.7A Pending CN117356707A (en) | 2023-10-30 | 2023-10-30 | Functional food composition for preventing and treating three-high symptoms and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117356707A (en) |
-
2023
- 2023-10-30 CN CN202311413503.7A patent/CN117356707A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
CN101972338B (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
CN102698137A (en) | Composition with blood pressure reducing function and preparation method of same | |
CN101502588B (en) | Composition for beauty treatment and removing blain and method for preparing the same | |
CN106804643A (en) | A kind of clinical laboratory Chinese medicine sterilizing thimerosal | |
CN101647921B (en) | Traditional Chinese medicine composition for preventing and treating peptic ulcer and chronic gastritis | |
CN102488814B (en) | Chinese medicinal composition for treating bovine mastitis | |
CN104306659B (en) | A kind of Chinese medicine composition for treating diabetes B | |
CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
CN108785594A (en) | A kind of Chinese herbal ointment formula and preparation method for intervening phlegm-dampness constitution | |
CN104208393A (en) | Traditional Chinese medicine composition for treating chicken infectious bronchitis and preparation method thereof | |
CN104161977B (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of infectious coryza of chicken and preparation method thereof | |
CN105497840A (en) | Soup capable of expelling dampness, removing heat and diminishing inflammation | |
CN1331495C (en) | Throat-clearing lozenge | |
CN117356707A (en) | Functional food composition for preventing and treating three-high symptoms and preparation method thereof | |
CN113499425A (en) | Composition for treating viral influenza and preparation method thereof | |
CN106237039A (en) | A kind of antibacterial cream of rhinitis and preparation method thereof | |
CN105343840A (en) | Traditional Chinese medicine for treating pneumonia for traditional Chinese medicine internal medicine department | |
CN111632080A (en) | Formula for treating drug eruption dermatitis, preparation method and application | |
CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
CN102274420A (en) | Chinese medicinal composition for treating acnes | |
CN104971294A (en) | Traditional Chinese medicine composition for preventing and treating cattle pneumonia and orally-taken preparation | |
US6444236B1 (en) | Compositon containing medicinal herbs and young antlers of cornu cervi | |
CN104623615A (en) | Medicine for treating asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |